Cantitate/Preț
Produs

Heart Failure: Frontiers in Cardiology

Editat de A. Kitabatake, S. Sasayama, G.S. Francis
en Limba Engleză Paperback – 23 feb 2012
Remarkable progress has been made in understanding and treating heart failure. Among other developments, angiotensin-converting enzyme inhibitors and b blockers have been found to have beneficial therapeutic effects, reinforcing the view that heart failure may be both a hemodynamic and a neurohumoral disorder. The Japanese Heart Failure Society was established to curb the threat of heart failure through research, education, and clinical practice. At the Societys 2nd Annual Scientific Meeting in Sapporo, molecular biologists, physiologists, clinicians, surgeons, and researchers in related fields met to strengthen professional bonds for the ultimate goal of preventing death from heart failure. This book contains presentations from the Sapporo conference that provide new insights into heart failure in the areas of pathophysiology, cardiac sudden death, medical and surgical treatment, and promising new gene therapy.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 35788 lei  6-8 săpt.
  Springer – 23 feb 2012 35788 lei  6-8 săpt.
Hardback (1) 36410 lei  6-8 săpt.
  Springer – 31 mar 2000 36410 lei  6-8 săpt.

Preț: 35788 lei

Preț vechi: 37672 lei
-5% Nou

Puncte Express: 537

Preț estimativ în valută:
6849 7203$ 5722£

Carte tipărită la comandă

Livrare economică 08-22 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9784431683339
ISBN-10: 443168333X
Pagini: 276
Ilustrații: XIV, 261 p.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 2000
Editura: Springer
Colecția Springer
Locul publicării:Tokyo, Japan

Public țintă

Research

Descriere

Remarkable progress has been made in understanding and treating heart failure. Among other developments, angiotensin-converting enzyme inhibitors and b blockers have been found to have beneficial therapeutic effects, reinforcing the view that heart failure may be both a hemodynamic and a neurohumoral disorder. The Japanese Heart Failure Society was established to curb the threat of heart failure through research, education, and clinical practice. At the Societys 2nd Annual Scientific Meeting in Sapporo, molecular biologists, physiologists, clinicians, surgeons, and researchers in related fields met to strengthen professional bonds for the ultimate goal of preventing death from heart failure. This book contains presentations from the Sapporo conference that provide new insights into heart failure in the areas of pathophysiology, cardiac sudden death, medical and surgical treatment, and promising new gene therapy.

Cuprins

Part 1 New Insights in Pathophysiology of Heart Failure: Neurohormones in Advanced Heart Failure. Recent Progress in the Natriuretic Hormone Research. Cytokines and Heart Failure: Pathophysiological Roles. Endothelial Dysfunction in Heart Failure. Apoptosis: Its Mechanism and Meaning in Heart Failure. Mechanisms of Cardioprotection with Ischemic Preconditioning. Role of NO in Myocardial Injury Induced by Oxidative Stress. Cardiac Remodeling: Role of Neovascularization in Heart Failure.- Part 2 Heart Failure and Cardiac Sudden Death: QT Prolongation Syndrome in CHF. ICD Therapy: Can they prevent sudden death in CHF patients? Arrhythmias in CHF: To treat or not to treat.- Part 3 Medical Treatment of Heart Failure: Beyond ACE Inhibitors: New Concepts of Clinical Practice Guideline For Heart Failure. AII Antagonism in Heart Failure: Evaluation of Losartan in the Elderly Trial. Beta-Blockers: Benefits and Risks from Beta-blockade Therapy. Future Prospects of Endothelin Antagonists in Heart Failure. Heart Failure: Potential Benefit of Growth Hormone Therapy. Adenosine and Cardioprotection: Its Implication in Heart Failure.- Part 4 Gene Therapy for Heart Failure: Current Status and Future Prospect: In vivo Gene Supplementation for the Therapy of Cadiomyopathy. Lessons From Beta2 Receptor Transgenic Mouse. In vivo transfection of cis element 'decoy' against NF-kappaB binding site prevents myocardial damage. Scar Tissues to Viable Myocytes.- Part 5 Surgical Treatment for Heart Failure: A New Paradigm beyond Cardiac Transplantation Treatment of Profound Heart Failure by Ventricular Assist System. Ventriculoplasty of the End-Stage Heart Failure 'Batista' operation and 'Dor' operation.

Caracteristici

Providing a wide range of works from molecular pathophysiology to surgical treatment